期刊
NANOMEDICINE
卷 5, 期 7, 页码 1065-1074出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.10.78
关键词
antiangiogenics; combination therapy; K/BxN arthritis model; nanotherapeutics; rheumatoid arthritis
资金
- NIH [AR056468, CA119342, HL073646, NS059302, HL094470]
Aim: This study examines the effect of combining the antiangiogenic effect of alpha(v)beta(3)-targeted fumagillin nanoparticles with the conventional antirheumatic drug methotrexate for the treatment of inflammatory arthritis. Method: Arthritis was induced in mice by K/BxN serum transfer, and disease activity was monitored by clinical score and change in ankle thickness. Groups of mice received nanoparticles or methotrexate as single therapy or nanoparticles and methotrexate as combination therapy. Results: We found that animals treated with a pulse dose of fumagillin nanoparticles followed by methotrexate had significantly improved and sustained clinical response compared with those treated with either agent alone. Histological analysis confirmed a significant decrease in inflammatory cell influx, bone erosions, cartilage damage and angiogenesis with the combination therapy. Conclusion: Analysis of plasma cytokine levels suggests that fumagillin nanoparticles enhanced the systemic anti-inflammatory effects of methotrexate. Antiangiogenic nanotherapy may represent a promising approach for the treatment of inflammatory arthritis when combined with a conventional antirheumatic drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据